Catalyst Pharmaceuticals (CPRX) Asset Utilization Ratio (2018 - 2026)
Catalyst Pharmaceuticals posted quarterly Asset Utilization Ratio of 0.53 for Q1 2026, down 12.71% year-on-year from 0.61 in Q1 2025, and down 2.97% on a QoQ basis from 0.55 in Q4 2025.
Catalyst Pharmaceuticals (CPRX) has 9 years of Asset Utilization Ratio data on file, last reported at 0.53 in Q1 2026.
- For the quarter ending Q1 2026, Asset Utilization Ratio fell 12.71% year-over-year to 0.53; the trailing twelve-month figure through Mar 2026 stood at 0.53 (down 12.71% YoY), and the FY2025 full-year result was 0.6, down 19.05% from the prior year.
- Asset Utilization Ratio for Q1 2026 stood at 0.53, down from 0.55 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.9 in Q4 2023 and bottomed at 0.53 in Q1 2026.
- The 5-year median for Asset Utilization Ratio is 0.63 (2022), against an average of 0.65.
- The widest annual swing landed in 2023, when Asset Utilization Ratio surged 49.16%; it then tumbled 32.81% in 2024.
- A 5-year view of Asset Utilization Ratio shows it stood at 0.6 in 2022, then soared by 49.16% to 0.9 in 2023, then sank by 32.81% to 0.61 in 2024, then fell by 9.79% to 0.55 in 2025, then slipped by 2.97% to 0.53 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.53 (Q1 2026), 0.55 (Q4 2025), and 0.57 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.85 |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn | 0.53 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.53 |
| Dec 31, 2025 | 0.55 |
| Sep 30, 2025 | 0.57 |
| Jun 30, 2025 | 0.59 |
| Mar 31, 2025 | 0.61 |
| Dec 31, 2024 | 0.61 |
| Sep 30, 2024 | 0.62 |
| Jun 30, 2024 | 0.64 |
| Mar 31, 2024 | 0.74 |
| Dec 31, 2023 | 0.90 |
| Sep 30, 2023 | 0.81 |
| Jun 30, 2023 | 0.71 |
| Mar 31, 2023 | 0.66 |
| Dec 31, 2022 | 0.60 |
| Sep 30, 2022 | 0.64 |
| Jun 30, 2022 | 0.66 |
| Mar 31, 2022 | 0.63 |
| Dec 31, 2021 | 0.61 |
| Sep 30, 2021 | 0.62 |
| Jun 30, 2021 | 0.62 |
| Mar 31, 2021 | 0.62 |
| Dec 31, 2020 | 0.65 |
| Sep 30, 2020 | 0.77 |
| Jun 30, 2020 | 0.96 |
| Mar 31, 2020 | 1.03 |
| Dec 31, 2019 | 0.98 |
| Sep 30, 2019 | 0.83 |
| Jun 30, 2019 | 0.60 |
| Mar 31, 2019 | 0.21 |
| Dec 31, 2018 | 0.01 |